



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kong-Hong Andy Choo, et al.

Examiner: Celine X. Qian

Serial No.: 09/728,552

Art Unit: 1636

Filed: December 2, 2000

Docket: 11445Z

For: NUCLEIC ACID MOLECULES COMPRISING
A NEOCENTROMERE

Dated: August 11, 2006

Confirmation No.: 3587

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: August 11, 2006


Xiaochun Zhu

08/15/2006 ZJUHA1 00000009 09728552

02 FC:1806

180.00 0P

1. Abeliovich, D. et al., "dup(10q) Lacking α -satellite DNA in Bone Marrow Cells of a Patient With Acute Myeloid Leukemia", *Cancer Genet Cytogenet*, 89:1-6 (1996);
2. Choo, K. H. Andy, "Chromatin Dynamics '97. Centromere DNA Dynamics: Latent Centromeres and Neocentromere Formation", *Am. J. Hum. Genet*, 61:1225-1233 (1997); and
3. Depinet, Theresa W., "Characterization of neo-centromeres in marker chromosomes lacking detectable alpha-satellite DNA", *Human Molecular Genetics*, 6(8):1195-1204 (1997).

The references were cited in a Supplementary European Search Report dated March 12, 2002 received from the European Patent Office. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(c), a check in the amount of \$180.00 is enclosed.

Respectfully submitted,



Xiaochun Zhu
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343
XZ:ab

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
11445Z

In Re Application Of: Kong-Hong Andy Choo, et al.

AUG 14 2006
PATENT & TRADEMARK OFFICE

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/728,552	December 2, 2000	Celine X. Qian	23389	1636	3587

Title: NUCLEIC ACID MOLECULES COMPRISING A NEOCENTROMERE

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☒ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.
11445Z

In Re Application of: **Kong-Hong Andy Choo, et al.**

AUG 14 2006
PATENT & TRADEMARK OFFICE

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/728,552	December 2, 2000	Celine X. Qian	23389	1636	3587

Title: **NUCLEIC ACID MOLECULES COMPRISING A NEOCENTROMERE**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☒ A check in the amount of **\$180.00** is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
- ☐ Charge the amount of
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to *Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450* [37 CFR 1.8(a)] on

August 11, 2006

(Date)


Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

Dated: **August 11, 2006**


Signature


Xiaochun Zhu
Registration No. 56,311
Scully, Scott, Murphy & Presser, P. C.
400 Garden City Plaza-STE 300
Garden City, New York 11530
(516) 742-4343

CC: XZ:ab

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
11445Z

In Re Application Of: **Kong-Hong Andy Choo, et al.**



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/728,552	December 2, 2000	Celine X. Qian	23389	1636	3587

Title: **NUCLEIC ACID MOLECULES COMPRISING A NEOCENTROMERE**

Address to:
**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

37 CFR 1.97(b)

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☒ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
11445Z

In Re Application of: **Kong-Hong Andy Choo, et al.**

AUG 14 2006

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/728,552	December 2, 2000	Celine X. Qian	23389	1636	3587

Title: **NUCLEIC ACID MOLECULES COMPRISING A NEOCENTROMERE**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☒ A check in the amount of **\$180.00** is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
- ☐ Charge the amount of
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

August 11, 2006

(Date)

Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: August 11, 2006

Xiaochun Zhu
Registration No. 56,311
Scully, Scott, Murphy & Presser, P. C.
400 Garden City Plaza-STE 300
Garden City, New York 11530
(516) 742-4343

CC: XZ:ab

Form PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No.

Serial No.

11445Z

09/728,552

**LIST OF PRIOR ART
CITED BY APPLICANT**

(Use several sheets if necessary)

Applicants

Kong-Hong Andy Choo, et al.

Filing Date

December 2, 2000

Group

1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*	DOCUMENT NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

1.	Abeliovich, D. et al., "dup(10q) Lacking α -satellite DNA in Bone Marrow Cells of a Patient With Acute Myeloid Leukemia", <i>Cancer Genet Cytogenet</i> , 89:1-6 (1996)
2.	Choo, K. H. Andy, "Chromatin Dynamics '97. Centromere DNA Dynamics: Latent Centromeres and Neocentromere Formation", <i>Am. J. Hum. Genet</i> , 61:1225-1233 (1997)
3.	Depinet, Theresa W., "Characterization of neo-centromeres in marker chromosomes lacking detectable alpha-satellite DNA", <i>Human Molecular Genetics</i> , 6(8):1195-1204 (1997)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.